Advertisement

Topics

Clovis Pops on Bristol-Myers Partnership; Intercept Dives on Weak Earnings: Biotech Movers

10:45 EDT 31 Jul 2017 | Topix

Shares of Clovis Oncology Inc. were down 7.4% to $90.80 in premarket trading on Monday, July 31. The Boulder, Colo.-based firm and Bristol-Myers Squibb Co. unveiled a collaboration to evaluate the combination of Bristol-Myers' s immunotherapy Opdivo and Clovis Oncology's poly polymerase inhibitor Rubraca in Phase 3 studies in advanced advanced ovarian cancer and advanced triple-negative breast cancers.

Original Article: Clovis Pops on Bristol-Myers Partnership; Intercept Dives on Weak Earnings: Biotech Movers

NEXT ARTICLE

More From BioPortfolio on "Clovis Pops on Bristol-Myers Partnership; Intercept Dives on Weak Earnings: Biotech Movers"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...